Pancreatic Cancer and Diabetes: Insights, Hypotheses, and Next Steps

Area of Science:

• Endocrinology
• Oncology
• Metabolism

Background:

• Pancreatic ductal adenocarcinoma (PDAC) is often preceded by new-onset diabetes (NOD) in individuals over 50.
• The precise causal relationship between PDAC and NOD remains unclear.
• NOD may represent an early clinical indicator for PDAC.

Purpose of the Study:

• To synthesize current clinical and experimental evidence on the link between PDAC and NOD.
• To provide an islet-centric perspective on how PDAC affects pancreatic endocrine function.
• To identify key uncertainties and prioritize future research directions.

Main Methods:

• Review of existing clinical and experimental studies.
• Synthesis of evidence from islet physiology and systemic metabolism.
• Distinguishing established PDAC findings from inferred mechanisms.

Main Results:

• Tumor-derived signals and microenvironmental changes in PDAC can impair beta-cell insulin secretion.
• PDAC disrupts the regulatory functions of alpha- and delta-cells.
• Several critical areas require further investigation, including the timing of systemic versus local drivers and the clinical significance of tumor signals.

Conclusions:

• PDAC significantly impacts pancreatic islet cell function, contributing to dysglycemia.
• Further research is needed to clarify the mechanisms underlying the PDAC-NOD association.
• Understanding these mechanisms could lead to earlier PDAC detection and improved patient outcomes.